Phase II proof of concept trial for APG 101 (Apogenix) is confirmed for Glioblastoma Multiforme - 30-Jul-2012

Apogenix announced the figures that confirm that the primary objective of its Phase II proof-of-concept trial investigating its lead product, APG101, as a second line treatment of Glioblastoma Multiforme (GBM), had been met, The company expects to unveil overall survival data from the study in the fourth quarter of 2012.In March 2012 the company reported that the primary objective of its 84-patient trial, which was to increase the percentage of patients reaching six-month-rate of progression-free survival (PFS6) by 100%, had been "exceeded substantially". Apogenix is looking for a partner to further develop the drug.

Related News

Positive results from Phase III study of Avastin (Genentech/Roche) in Brain Cancer patients

NKTR 102 (Nektar) update on cancer trials

Phase II proof of concept trial for APG 101 (Apogenix) is confirmed for Glioblastoma Multiforme

NovoTTF-100A (NovoCure) shows positive Phase III results for Brain Cancer

Yervoy (BMS) in Brain Metastases study

APG101 (Apogenix) meets primary endpoint in Phase II trial for Glioblastoma Multiforme

NovoTTF-100A (NovoCure) therapy achieves encouraging long term survival time for Glioblastoma patients

NovoTTF-100A system is FDA approved for Glioblastoma

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Phase III study of Sufentanil NanoTab PCA System (AcelRx Pharmaceuticals) meets primary endpoint for...

23 May 2013

Top-line data from a Phase III study of Sufentanil NanoTab PCA System, from AcelRx Pharmaceuticals, shows that the primary efficacy endpoint...

Read full article

FreeStyle InsuLinx Blood Glucose Monitoring System (Abbott) is recalled in the USA

22 May 2013

The Freestyle Insulinx Blood Glucose Monitoring System has been recalled by Abbott Diabetes Care in the United States. The FDA has assigned...

Read full article